Ma Yinglong's "erythromycin ointment" spot check is unqualified

According to the "notice on drug quality and safety in Beijing in the second half of 2019" issued by the State Food and drug administration, the "erythromycin ointment" (batch number 190126) produced by Ma Yinglong Pharmaceutical Group Co., Ltd was found to be unqualified in the "content determination" item by Beijing Institute of drug inspection, and the source of the tested product was Beijing xuannei Pharmaceutical Co., Ltd The total number of molds and yeasts in the batch number of "Yinqiao cold wind capsule" (batch number 20181002) produced by Heilongjiang sunflower Pharmaceutical Co., Ltd is unqualified, and the source of the sample is Beijing Jingmeng Huikang Pharmaceutical Co., Ltd Ma Yinglong Pharmaceutical Group Co., Ltd has previously been listed in the "black list" due to unqualified products: on May 11, 2017, the "Notice of the State Food and Drug Administration on 11 batches of unqualified drugs (2017 No 74)" showed that the "Diosmin tablets" (batch No 150609) produced by Ma Yinglong was found to be unqualified in the "content determination" by Dalian Drug Inspection Institute, and the samples were inspected The source is Huadong pharmaceutical Huzhou Co., Ltd From 2018 to 2019, Chengdu Oukang Pharmaceutical Co., Ltd invested by Ma Yinglong was punished twice for environmental violations Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.